ALR-27 is a FLAP (5-lipoxygenase-activating protein) antagonist with anti-inflammatory activity; it effectively inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDMs without significantly directly inhibiting 5-LOX; it reduces the production of prostaglandins and leukotrienes (LTs) in neutrophils and enhances the production of specialized pro-resolving mediators in specific human macrophage phenotypes.